AXGN

Axogen's stock experienced significant movement in the past six months, driven by financial results and regulatory milestones. The stock increased by 28.5% between January 1st, 2026, and May 9th, 2026. Key events include the FDA approval of the Biologics License Application (BLA) for Avance® in December 2025, the completion of an upsized public offering in January 2026, the report of Fourth Quarter and Full-Year 2025 financial results in February 2026, and the report of strong First Quarter 2026 financial results in April 2026. Analysts have generally maintained a "Moderate Buy" consensus rating for AXGN, but there have been reports of insider selling.